Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:624 (18 March), doi:10.1136/bmj.332.7542.624-b
Janice Hopkins Tanne
News York
| The first 150 words of the full text of this article appear below. |
The US Food and Drug Administration "created a regulatory catch 22 to justify the predetermined political decision to block over the counter sales of [the emergency contraceptive] Plan B [levonorgestrel]," representative Henry Waxman, a California Democrat, claimed last week.
He sent a seven page letter relying on "previously undisclosed documents" to Andrew von Eschenbach, the acting commissioner of the FDA. In the letter he charges that the FDA "created the situation it now protests as too complex to solve" and "seriously mischaracterised its consideration of the regulatory questions at stake."
He wrote that the documents "further undermine the agency's contention that the Plan B decision was based on legitimate science-based factors." He asked Dr von Eschenbach to explain the FDA's action by 27 March 2005.
Plan B has been available on prescription in the United States since 1999. Barr Pharmaceuticals, the manufacturer, applied to the FDA to make it available
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?